Surveillance of Healthcare-associated Infections & Antimicrobial Resistance

NCT05734391 | Enrolling By Invitation

• 1 other identifier: 851492
• Study Type: observational
• Target: 1,500
• Locations: 2 countries
• Sites: 2

Brief Summary

The aims of this project, called "Surveillance of Healthcare-associated infections \& Antimicrobial Resistance", or "SHARE", are to 1) enhance laboratory capacity to detect emerging AMR patterns; 2) strengthen hospital epidemiology programs to use data to prevent, detect, and contain emerging AMR threats; 3) deploy study teams to answer critical public health surveillance questions, and 4) to build a national network of infection prevention and control (IPC) resources to prevent, detect, and contain emerging infectious disease threats

Conditions

Antimicrobial Resistance

Outcome Measures

Primary Outcomes (1)

• Expertise

  Ultimately, the goal of the SHARE project is to assemble the expertise and infrastructure needed to build a resilient HAI/AMR surveillance system fully-incorporated into MOHW's surveillance activities. The project aims to build capacity, both material and knowledge, in existing laboratory and IPC teams to face the dynamic challenges posed by HAIs and AMR

  12 months

Secondary Outcomes (1)

• Feasibility and Surveillance

  12 months

Study Arms (1)

inpatients

Individuals in inpatient wards

Diagnostic Test: Routine Infection control

Interventions

Routine Infection control DIAGNOSTIC_TEST

routine part of hospital IPC activities

Also known as: Surveillance activity

inpatients

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

individuals being admitted to participating wards, of all clinical conditions, genders, and ages, meeting the inclusion/exclusion criteria

You may qualify if:

• hospital inpatient admission to participating wards.

You may not qualify if:

• diagnosis of a bleeding disorder
• platelet counts of \<50,000
• diagnosis of coagulopathy
• presence of active bleeding
• inability to have a nares swab collected due to some other condition where nasal swabbing would be contraindicated
• inability to have a rectal swab collected due to some other condition where rectal swabbing would be contraindicated

Sponsors & Collaborators

• University of Pennsylvania: lead

Study Sites (2)

University of Pennsylvania School of Medicine

Philadelphia, Pennsylvania, 19104, United States

Location

Princess Marina Hospital

Gaborone, 267, Botswana

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Nasal and rectal swabs

Study Officials

• Ebbing Lautenbach, MD, MPH, MSCE

  University of Pennsylvania

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Corrado Cancedda

Study Record Dates

• First Submitted: February 8, 2023
• First Posted: February 21, 2023
• Study Start: October 1, 2022
• Primary Completion (Estimated): December 20, 2027
• Study Completion (Estimated): December 20, 2027
• Last Updated: September 12, 2025

Record last verified: 2025-09

Locations

BO (1); US (1)